Pregnancy

Data Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting

Staff October 11, 2023

Studies address cost-effectiveness and budget impact of INPEFA, an inhibitor of SGLT2 and SGLT1 INPEFA recently approved by FDA for treatment...

Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society’s Annual Meeting at ObesityWeek ®

Staff October 10, 2023

BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...

Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer

Staff October 9, 2023

Mr. Garner brings over 25 years of pharmaceutical industry experienceTHE WOODLANDS, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals,...

Digital Health Solution, Dentistry.One, Bridges the Gap Between Dental and Medical Care for Improved Health and Lower Costs – Visit Us at HLTH 2023

Staff October 6, 2023

Booth #2450-22 (DiMe Virtual First Care Pavilion) and Booth #4950-5 (CareQuest Systemic Health Pavilion)METUCHEN, N.J.--(BUSINESS WIRE)--Dentistry.One, a virtual-first dental care...

ANY LAB TEST NOW Honored With Another Coveted Spot on Franchise Times Top 400 List

Staff September 28, 2023

Direct Access Lab Company is Among Leaders in the Health and Medical SectorATLANTA, GA / ACCESSWIRE / September 28, 2023...

Lexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023

Staff September 28, 2023

INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure SCORED was one of two randomized, double-blind, placebo-controlled Phase...

Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023

Staff September 27, 2023

WEST CHESTER, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology...

Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate

Staff September 27, 2023

The first academic center activated to enroll, led by an instrumental investigator who participated in Femasys’ earlier FemBloc studies -FemBloc...

Lexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)

Staff September 26, 2023

INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure LX9211 is an investigational, non-opioid treatment for diabetic peripheral...

Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)

Staff September 26, 2023

--Reached agreement with FDA on single Phase 3 clinical trial design to expand treatment population to include all hospitalized adult...

SIKLOS® (hydroxyurea) is now covered by State Medicaid programs in 19 states

Staff September 21, 2023

SIKLOS® (hydroxyurea) is now covered by State Medicaid programs in 19 states Medunik USA (member of Duchesnay Pharmaceutical Group) is...

Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan

Staff September 21, 2023

FILSPARI® (sparsentan) achieved a clinically meaningful difference vs. irbesartan in eGFR total slope (1.0 mL/min/1.73m2 per year) and eGFR chronic...

Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023

Staff September 20, 2023

MIAMI, FL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...

Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control

Staff September 20, 2023

ATLANTA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs...

Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity

Staff September 19, 2023

BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...

GE HealthCare Awarded a $44 Million Grant to Develop Artificial Intelligence-Assisted Ultrasound Technology Aimed at Improving Outcomes in Low-and-Middle-Income Countries

Staff September 18, 2023

Grant from Bill & Melinda Gates Foundation will facilitate development of AI-assisted applications and tools to enable healthcare professionals with...

iSpecimen Expands Provider Network to Enhance Support for Women’s Health Research

Staff September 13, 2023

Additional Providers Increase Biospecimen Access for Researchers Focused on Cervical, Uterine and Breast Cancers, as well as Reproductive Health, Cardiovascular...

Baylor Genetics Announces Neurodevelopmental Disorders Test Panel to Help Healthcare Providers Diagnose Patients with Intellectual Disabilities or Developmental Delays

Staff September 12, 2023

New Test Analyzes Highly Curated Set of 236 Genes Most Associated with Autism Spectrum Disorder, Intellectual Disabilities, and Developmental Delay.HOUSTON,...

Intra-Cellular Therapies Announces Presentations at Psych Congress 2023 Including Positive Results from Study 403 in Mixed Features

Staff September 11, 2023

NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development...

Rhythm Pharmaceuticals Announces Update to September Conference Participation

Staff September 8, 2023

BOSTON, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...